Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04586270 · ClinicalTrials.gov registry record · Phase 1
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04586270 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 47 participants.
The verdict
NCT04586270, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer.
Interventions
- DRUG TAS0612
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04586270
The ClinicalTrials.gov registry entry for NCT04586270 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS0612 is the first listed.
NCT04586270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04586270 about?
NCT04586270 is a clinical study titled "A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer". The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer.
What is the current status of trial NCT04586270?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2020-10-15. Estimated completion is 2024-11-14.
What interventions are being tested in trial NCT04586270?
The interventions under investigation include: TAS0612 (DRUG).
Who is sponsoring clinical trial NCT04586270?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.